Karen E. Knudsen, PhD
A vaccine targeting GUCY2C, a commonly overexpressed protein in patients with early-stage colorectal cancer (CRC), induced antibody and T-cell responses toward the specified target and demonstrated an acceptable safety profile in this patient population, according to results of a first-in-human phase I trial (NCT01972737).1,2
“The goal of the study to begin this fall is to show that version 2.0 of the vaccine is even better and that it may benefit a much bigger group of the overall cancer patient population,” Snook said in the press release.
- Snook A, Baybutt T, Xiang B, et al. Split tolerance permits safe AD5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. J Immunother Can. 2019;7(104). doi: 10.1186/s40425-019-0576-2.
- Novel Vaccine for Colorectal Cancer Shows Positive Phase I Results. Jefferson Health. Published April 29, 2019. https://bit.ly/2PLjDvo. Accessed April 30, 2019.
... to read the full story